|1.||Deacon, Steve: 6 articles (08/2012 - 03/2007)|
|2.||Ebert, Bjarke: 6 articles (07/2012 - 02/2006)|
|3.||Lundahl, Jonas: 4 articles (08/2012 - 03/2007)|
|4.||Walsh, James K: 4 articles (10/2011 - 05/2007)|
|5.||Deacon, S: 3 articles (08/2012 - 11/2007)|
|6.||Wang, Yun: 2 articles (10/2014 - 01/2013)|
|7.||Kong, Shuzhen: 2 articles (10/2014 - 01/2013)|
|8.||Wu, Zheng: 2 articles (10/2014 - 01/2013)|
|9.||Staner, Luc: 2 articles (08/2012 - 03/2007)|
|10.||Lundahl, J: 2 articles (08/2012 - 11/2007)|
|1.||Sleep Initiation and Maintenance Disorders (Insomnia)
02/15/2010 - "Gaboxadol was generally well tolerated over 3 months in Study 1, and over 12 months in Study 2. Gaboxadol 15 mg showed variable efficacy on measures of sleep duration and onset at 3 months in adult patients with Primary Insomnia in these studies and appeared to be more effective in women than men. "
03/01/2007 - "These findings suggest that gaboxadol may be a useful treatment for insomnia."
08/01/2012 - "Enhanced slow wave sleep and improved sleep maintenance after gaboxadol administration during seven nights of exposure to a traffic noise model of transient insomnia."
05/01/2007 - "Evaluate the hypnotic efficacy of gaboxadol, a selective extrasynaptic GABAA agonist (SEGA), in a phase advance model of transient insomnia. "
02/15/2010 - "Effect of gaboxadol on patient-reported measures of sleep and waking function in patients with Primary Insomnia: results from two randomized, controlled, 3-month studies."
|2.||Movement Disorders (Movement Disorder)
09/01/1982 - "The maximal short-term dose of THIP was 10 to 25 mg, whereas in the longer-term study the highest daily dose ranged from 20 to 120 mg. Tardive dyskinesia was unchanged during THIP treatment, but preexisting parkinsonism increased significantly and eye-blinking rates decreased. "
09/01/1982 - "Although THIP is not an effective new treatment for tardive dyskinesia, more specific GABA agonists should be evaluated in future studies of this syndrome."
06/01/1987 - "A double-blind, placebo-controlled trial of gamma-vinyl gamma-aminobutyric acid (GVG) and 4,5,6,7-tetrahydroisoxazolo-(5,4-c) pyridine-3-ol (THIP) was carried out in drug-free schizophrenic patients with tardive dyskinesia. "
05/07/2005 - "These results reinforce the involvement of GABAergic hypofunction in the expression of oral dyskinesias, and support the potential therapeutic use of THIP and baclofen in the treatment of oral dyskinesias."
09/01/1982 - "The effect of tetrahydroisoxazolopyridinol (THIP) in tardive dyskinesia: a new gamma-aminobutyric acid agonist."
02/08/1980 - "No protection against seizures was seen after THIP, 1-4 mg/kg, intraperitoneally in mice. "
01/01/2013 - "We then showed that injection of THIP (5 μM), a selective agonist for extrasynaptic GABAA receptors at low concentration, into rat brain also suppressed epileptiform burst activity and behavioral seizures in vivo. "
01/01/2011 - "Withdrawal of tetrahydroisoxazolopyridine (THIP) may cause seizures. "
01/01/2004 - "Withdrawal of tetrahydroisoxazolopyridine (THIP) may cause seizures. "
01/01/2001 - "Withdrawal of THIP may cause seizures. "
|4.||Major Depressive Disorder (Major Depressive Disorders)
07/01/2012 - "The aim of this proof-of-concept study was to compare the efficacy of escitalopram (20 mg/d) in combination with fixed doses of gaboxadol to escitalopram (20 mg) in the treatment of patients with severe major depressive disorder (MDD). "
07/01/2012 - "Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder."
|5.||Fragile X Syndrome (Martin Bell Syndrome)
|1.||gamma-Aminobutyric Acid (GABA)
|2.||GABA Agonists (GABA Receptor Agonists)
|4.||GABA-A Receptor Agonists
|10.||GABA-A Receptors (GABA(A) Receptor)
|1.||Investigational Therapies (Experimental Therapy)
|3.||Self Administration (Administration, Self)